Holen Sie sich die Stockscreener-App
2.535
2.87%
-0.075
Schlusskurs vom Vortag:
$2.61
Offen:
$2.6
24-Stunden-Volumen:
176.96K
Relative Volume:
0.99
Marktkapitalisierung:
$72.67M
Einnahmen:
$1.04M
Nettoeinkommen (Verlust:
$-32.07M
KGV:
-0.3931
EPS:
-6.4491
Netto-Cashflow:
$-26.12M
1W Leistung:
-7.14%
1M Leistung:
-15.50%
6M Leistung:
-42.12%
1J Leistung:
-22.48%
1-Tages-Spanne:
$2.53
$2.6465
1-Wochen-Bereich:
$2.52
$2.719
52-Wochen-Spanne:
$2.52
$5.86
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie VTGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VTGN | 2.54 | 72.67M | 1.04M | -32.07M | -26.12M | -6.4491 |
| VRTX | 450.01 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.02 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.85 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.66 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World
Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online
Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada
Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks
Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire
Vistagen reports Q2 EPS (42c), consensus (39c) - TipRanks
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com
Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire
Vistagen to Present Breakthrough SAD Treatment Data at 2024 NEI Congress | VTGN Stock News - StockTitan
Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise
VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Generalized Anxiety Disorder Pipeline 2024: Clinical Trials - openPR
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN
Mental Disorder Treatment Market Global Industry Forecast - openPR
Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise
Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance
Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia
Vistagen advances phase 3 trial for social anxiety treatment - Investing.com
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - StockTitan
All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance
Mental Disorder Treatment Market Expected to Expand at a Steady - openPR
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World
Mental Disorder Treatment Market Detailed In New Research - openPR
Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada
Vistagen shareholders approve board nominees and executive pay - Investing.com
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat
The Globe and Mail - The Globe and Mail
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - MSN
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):